Get the Stockscreener App
113.99
0.38%
-0.44
Pre-market:
113.84
-0.15
-0.13%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $113.99, with a volume of 7.65M.
It is down -0.38% in the last 24 hours and up +10.34% over the past month.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$114.43
Open:
$113.145
24h Volume:
7.65M
Relative Volume:
1.08
Market Cap:
$141.96B
Revenue:
$28.75B
Net Income/Loss:
$480.00M
P/E Ratio:
308.08
EPS:
0.37
Net Cash Flow:
$10.31B
1W Performance:
-1.26%
1M Performance:
+10.34%
6M Performance:
+37.07%
1Y Performance:
+51.82%
1-Day Range:
$112.82
$114.87
1-Week Range:
$112.82
$119.96
52-Week Range:
$62.07
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
113.99 | 141.96B | 28.75B | 480.00M | 10.31B | 0.37 |
|
LLY
Lilly Eli Co
|
821.86 | 781.10B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
212.06 | 374.36B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.85 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
74.79 | 332.00B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
93.35 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Gilead Sciences CFO sells $2.1 million in stock - Investing.com
Gilead Pushes PrEP Envelope As ViiV Explores Self-Administered, Long-Acting Drugs - Citeline News & Insights
Gilead Sciences announces executive departure and interim appointment By Investing.com - Investing.com South Africa
Gilead Presents New HIV Treatment And Cure Research Data - AOL
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive - Zacks Investment Research
Analyst Says Gilead Sciences (GILD) is a ‘Big Liquid’ Stock You Should Pay Attention To - Insider Monkey
Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data - Simply Wall St
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV - BioPharma Dive
Bernstein reiterates Gilead stock Outperform with $120 target By Investing.com - Investing.com South Africa
Gilead Presents Encouraging Long-term Data For Biktarvy In People With HIV And HBV Coinfection - Nasdaq
Pharmalittle: We're reading about a Roche deal for an obesity drug, a Gilead HIV drug and more - STAT
The Zacks Analyst Blog Highlights Exelon, Gilead Sciences, Plains All American Pipeline, Sportradar and Cintas - Nasdaq
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts - BioSpace
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option - BioSpace
Gilead to move once-yearly lenacapavir into Phase III for HIV prevention - FirstWord Pharma
Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales & Clinical Trials Insight 2030: New Report Highlights 600+ Bispecific Antibodies in Clinical Trials Worldwide - GlobeNewswire Inc.
Gilead reports high efficacy in HIV and HBV treatment study By Investing.com - Investing.com South Africa
Gilead Sciences (GILD) Presents New HIV Treatment and Cure Research Data - StreetInsider.com
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV - News-Medical.Net
Gilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals - The Financial Express
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success - Clinical Trials Arena
Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79 - Simply Wall St
Proficio Capital Partners LLC Acquires Shares of 339,489 Gilead Sciences, Inc. (NASDAQ:GILD) - Defense World
Morgan Stanley Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - Defense World
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavirSan Francisco Business Times - The Business Journals
Gilead's Once-Yearly Lenacapavir Formulations Show Sustained Efficacy for HIV PrEP in Phase 1 Study - Contagionlive.com
Gilead posts Phase 1 data for annual HIV PrEP drug (GILD) - Seeking Alpha
Gilead reports progress in HIV prevention with lenacapavir By Investing.com - Investing.com South Africa
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3 - FiercePharma
Gilead Sciences Once-yearly HIV Prevention Treatment Safe, Well Tolerated in Study -March 11, 2025 at 02:14 pm EDT - Marketscreener.com
Gilead presents data for once-yearly lenacapavir for HIV prevention - TipRanks
Gilead reports progress in HIV prevention with lenacapavir - Investing.com
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection - STAT
Gilead Sciences (GILD) Presents First Clinical Data for Investigational Once-Yearly Lenacapavir for HIV Prevention - StreetInsider.com
Gilead Sciences Presents First Clinical Data For Investigational Once-Yearly Lenacapavir For HIV Prevention - Marketscreener.com
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet - Business Wire
Gilead at Leerink Conference: Cell Therapy’s Promising Future By Investing.com - Investing.com UK
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts - Benzinga
Morgan Stanley Adjusts Price Target on Gilead Sciences to $130 From $123, Keeps Overweight Rating - Marketscreener.com
Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV - European Biotechnology News
Gilead Sciences's Options: A Look at What the Big Money is Thinking - Benzinga
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Buy Gilead Sciences (GILD) Stock at 52-Week Highs? - Yahoo Finance
Buy Gilead Sciences (GILD) Stock At 52-Week Highs? - Barchart
Gilead Sciences stock hits 52-week high at $117.42 By Investing.com - Investing.com South Africa
Gilead Sciences stock hits 52-week high at $117.42 - Investing.com
P/E Ratio Insights for Gilead Sciences - Benzinga
Gilead Sciences' (NASDAQ:GILD) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
Gilead Sciences, Inc. to Host Earnings Call - ACCESS Newswire
Bank of America Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - Defense World
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):